Clinical

Intermittent hypoxia sensitizes control centers in the brain, noted Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, and medical director, Sleep-Wake Center, University of Utah.

Among patients with glaucoma, diffuse rather than focal glaucomatous macular damage was associated with diminished facial recognition and contrast sensitivity, according to results of a cohort study published in JAMA Ophthalmology.

Intravenous (IV) iron reduced rehospitalization risk among patients hospitalized with acute heart failure (HF) and low iron, according to research presented at the American Heart Association’s Scientific Sessions 2020.

Combination therapy plays a central role in treating pulmonary arterial hypertension (PAH), and 2 abstracts presented at the CHEST annual meeting highlighted real-world treatment patterns.

Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses a new treatment option for beta thalassemia.

Investigating circulating tumor DNA is a top priority for patients with diffuse large B-cell lymphoma, noted Michael R. Green, PhD, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center.

New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma.

Findings published in BMC Ophthalmology suggest that during diagnosis and follow-up of glaucoma with high myopia, more attention ought to be focused on structure and functional defects in macular areas.

Compared with treprostinil, selexipag carried a 47% reduced risk of pulmonary arterial hypertension (PAH)-related hospitalization and 46% reduced risk of all-cause hospitalization.

Research behind the therapy could lead to other discoveries about heart disease as well as the aging process.

Most patients who are diagnosed with acute myeloid leukemia are in middle or old age. The relatively small number who are diagnosed earlier in life can be subject to long-term health risks due to their treatment.

Authors in the Journal of Clinical Oncology discuss hypotheses on the differences in mutations and implications for treatment with PARP inhibitors.

Using DIXON, T2 mapping, and diffusion tensor imaging, the researchers obtained quantitative MRI for 31 patients with spinal muscular atrophy (SMA) types 2 and 3.

Mounting evidence is supporting the use of poly ADP-ribose polymerase (PARP) inhibitors in prostate cancer, according to a new study.

The study compared females and males who suffer from migraines and other painful conditions who took part in a national health survey in Spain.

Results of the artificial intelligence (AI) model were consistent no matter which immune checkpoint inhibitor (ICI) therapy patients received, suggesting that some biomarkers are not necessarily specific to the checkpoint target.

The mortality risk differs for the 3 endothelin receptor antagonists approved to treat pulmonary arterial hypertension (PAH) in elderly patients; however, a direct comparison in a controlled trial is still needed to confirm results.

The oral selective inhibitor of nuclear export could provide a new therapeutic avenue in daratumumab-naive patients with relapsing refractory multiple myeloma (RRMM).

A new analysis of CREDENCE data showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor worked in advanced disease and without causing acute kidney injury.

Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discussed the potential complications for patients with beta thalassemia associated with iron overload and the significance of chelation therapy.

Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.

Women filling a prescription for female hormone therapy (FHT), and presumably taking FHT, are not at increased risk of retinal artery or retinal vein occlusions.

Results from a phase 3 study of Xywav in adult patients with idiopathic hypersomnia exhibited its potential to address this unmet medical need.

While migraine was more manifest in some patients during the pandemic, others were able to adopt healthier habits, said Peter McAllister, MD, a neurologist, board certified headache specialist, and medical director of the New England Institute for Neurology and Headache.